Literature DB >> 18452182

Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome.

Ning Weng1, Ivan Jeanne Weiler, Allison Sumis, Elizabeth Berry-Kravis, William T Greenough.   

Abstract

Lack of production of the Fragile X Mental Retardation Protein (FMRP) leads to changes in dendritic morphology and resultant cognitive and behavioral manifestations characteristic of individuals with Fragile X syndrome (FXS). FMRP is an RNA-binding protein that is believed to regulate the translation of a large number (probably over 100) of other proteins, leading to a complex and variable set of symptoms in FXS. In a mouse model of FXS, we previously observed delayed initiation of synaptically localized protein synthesis in response to neurotransmitter stimulation, as compared to wild-type mice. We now likewise have observed delayed early-phase phosphorylation of extracellular-signal regulated kinase (ERK), a nodal point for cell signaling cascades, in both neurons and thymocytes of fmr-1 KO mice. We further report that early-phase kinetics of ERK activation in lymphocytes from human peripheral blood is delayed in a cohort of individuals with FXS, relative to normlal controls, suggesting a potential biomarker to measure metabolic status of disease for individuals with FXS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452182     DOI: 10.1002/ajmg.b.30765

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  30 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

Review 2.  Taking STEPs forward to understand fragile X syndrome.

Authors:  Susan M Goebel-Goody; Paul J Lombroso
Journal:  Results Probl Cell Differ       Date:  2012

3.  Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.

Authors:  C A Hoeffer; E Sanchez; R J Hagerman; Y Mu; D V Nguyen; H Wong; A M Whelan; R S Zukin; E Klann; F Tassone
Journal:  Genes Brain Behav       Date:  2012-02-15       Impact factor: 3.449

4.  LTP induction translocates cortactin at distant synapses in wild-type but not Fmr1 knock-out mice.

Authors:  Ronald R Seese; Alex H Babayan; Adam M Katz; Conor D Cox; Julie C Lauterborn; Gary Lynch; Christine M Gall
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

5.  Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110β-selective inhibitor.

Authors:  Christina Gross; Gary J Bassell
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 6.  Pharmacotherapy for Fragile X Syndrome: Progress to Date.

Authors:  Matthew H Davenport; Tori L Schaefer; Katherine J Friedmann; Sarah E Fitzpatrick; Craig A Erickson
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 7.  Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Authors:  Christina Gross; Elizabeth M Berry-Kravis; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

8.  Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.

Authors:  Christina Gross; Mika Nakamoto; Xiaodi Yao; Chi-Bun Chan; So Y Yim; Keqiang Ye; Stephen T Warren; Gary J Bassell
Journal:  J Neurosci       Date:  2010-08-11       Impact factor: 6.167

Review 9.  Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back.

Authors:  Christina Gross; Anne Hoffmann; Gary J Bassell; Elizabeth M Berry-Kravis
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

10.  A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder.

Authors:  Logan K Wink; Ryan Adams; Paul S Horn; Charles R Tessier; Andrew P Bantel; Michael Hong; Rebecca C Shaffer; Ernest V Pedapati; Craig A Erickson
Journal:  J Autism Dev Disord       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.